{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:38:17Z","timestamp":1792669097307,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","award":["14270"],"award-info":[{"award-number":["14270"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00855-5","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:07Z","timestamp":1792665727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards meaningful outcome measures for health economic evaluations in skin cancer"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2035-6277","authenticated-orcid":false,"given":"Annick","family":"Meertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Annemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Verstraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Hoorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"855_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40273-024-01389-5","volume":"42","author":"A Meertens","year":"2024","unstructured":"Meertens A, Van Coile L, Van Iseghem T, Brochez L, Verhaeghe N, Hoorens I. Cost-of-Illness of Skin Cancer: A Systematic Review. PharmacoEconomics. 2024;42:751\u201365. https:\/\/doi.org\/10.1007\/s40273-024-01389-5.","journal-title":"PharmacoEconomics"},{"key":"855_CR2","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1038\/s41598-025-90485-3","volume":"15","author":"L Zhou","year":"2025","unstructured":"Zhou L, Zhong Y, Han L, Xie Y, Wan M. Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990\u20132021. Sci Rep Nat Publishing Group. 2025;15:5996. https:\/\/doi.org\/10.1038\/s41598-025-90485-3.","journal-title":"Sci Rep Nat Publishing Group"},{"key":"855_CR3","doi-asserted-by":"publisher","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes [Internet]. Oxford: Oxford University Press; 2005 [cited 2026 Mar 27]. https:\/\/doi.org\/10.1093\/oso\/9780198529446.001.0001.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"855_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/CEJ.0000000000000056","volume":"24","author":"LG Gordon","year":"2015","unstructured":"Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: A systematic review. Eur J Cancer Prev. 2015;24:141\u20139. https:\/\/doi.org\/10.1097\/CEJ.0000000000000056.","journal-title":"Eur J Cancer Prev"},{"key":"855_CR5","unstructured":"4 Economic evaluation | NICE technology appraisal and highly specialised technologies guidance: the manual | Guidance | NICE [Internet]. NICE. 2022 [cited 2026 Apr 17]. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2. Accessed 17 Apr 2026."},{"key":"855_CR6","doi-asserted-by":"publisher","unstructured":"Neyt M, Thiry N, Cleemput I. Belgische richtlijnen voor economische evaluaties en budgetimpact analyses: derde editie. Method Brussel Federaal Kenniscentrum voor de Gezondheidszorg (KCE). 2025;KCE Reports 400\u00a0C. https:\/\/doi.org\/10.57598\/R400C","DOI":"10.57598\/R400C"},{"key":"855_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jval.2024.04.021","volume":"27","author":"NJ Devlin","year":"2024","unstructured":"Devlin NJ, Drummond MF, Mullins CD. Quality-Adjusted Life Years, Quality-Adjusted Life-Year-Like Measures, or Neither? The Debate Continues. Value Health. 2024;27:689\u201391. https:\/\/doi.org\/10.1016\/j.jval.2024.04.021.","journal-title":"Value Health"},{"key":"855_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40273-015-0311-x","volume":"33","author":"L van de Wetering","year":"2015","unstructured":"van de Wetering L, van Exel J, Bobinac A, Brouwer WBF. Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. PharmacoEconomics. 2015;33:1289\u2013300. https:\/\/doi.org\/10.1007\/s40273-015-0311-x.","journal-title":"PharmacoEconomics"},{"key":"855_CR9","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1111\/jdv.18349","volume":"36","author":"I Hoorens","year":"2022","unstructured":"Hoorens I, Waalboer-Spuij R, Van Coile L, Debaveye M, Shen A, Verhaeghe E, et al. Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a cross-sectional study. J Eur Acad Dermatol Venereol JEADV. 2022;36:e906\u20137. https:\/\/doi.org\/10.1111\/jdv.18349.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"855_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","volume":"20","author":"NS McClure","year":"2017","unstructured":"McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value Health. 2017;20:644\u201350. https:\/\/doi.org\/10.1016\/j.jval.2016.11.015.","journal-title":"Value Health"},{"key":"855_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2022.04.059","volume":"87","author":"DI Schlessinger","year":"2022","unstructured":"Schlessinger DI, Reynolds KA, Dirr MA, Ibrahim SA, Yanes AF, Lazaroff JM, et al. Development of a core outcome set for basal cell carcinoma. J Am Acad Dermatol. 2022;87:573\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.059.","journal-title":"J Am Acad Dermatol"},{"key":"855_CR12","doi-asserted-by":"publisher","unstructured":"Reynolds Ka, Schlessinger Di, Yanes Af, Godinez-Puig V, Chen Br et al. Kurta A o.,. Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. Br J Dermatol. 2021;184:1113\u201322. https:\/\/doi.org\/10.1111\/bjd.19693.","DOI":"10.1111\/bjd.19693"},{"key":"855_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/DSS.0000000000001756","volume":"45","author":"TV Cartee","year":"2019","unstructured":"Cartee TV, Alam M, Armbrecht ES, Behera A, Lawrence N, Bordeaux JS, et al. Patient-Centered Outcomes for Skin Cancer Management: Utilization of a Patient Delphi Process to Identify Important Treatment Themes. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2019;45:246\u201353. https:\/\/doi.org\/10.1097\/DSS.0000000000001756.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al"},{"key":"855_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy Amsterdam Neth. 1990;16:199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9.","journal-title":"Health Policy Amsterdam Neth"},{"key":"855_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40258-024-00919-8","volume":"23","author":"C Mukuria","year":"2025","unstructured":"Mukuria C, Rowen D, Mulhern B, McDool E, Kharroubi S, Bjorner JB, et al. The Short Form 6 Dimensions (SF-6D): Development and Evolution. Appl Health Econ Health Policy. 2025;23:19\u201333. https:\/\/doi.org\/10.1007\/s40258-024-00919-8.","journal-title":"Appl Health Econ Health Policy"},{"key":"855_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/07853890109002086","volume":"33","author":"H Sintonen","year":"2001","unstructured":"Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;33:328\u201336. https:\/\/doi.org\/10.3109\/07853890109002086.","journal-title":"Ann Med"},{"key":"855_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095\u2013108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002.","journal-title":"Med Care"},{"key":"855_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jval.2024.04.018","volume":"27","author":"RJ Willke","year":"2024","unstructured":"Willke RJ, Pizzi LT, Rand LZ, Neumann P. The Value of the Quality-Adjusted Life Years. Value Health. 2024;27:702\u20135. https:\/\/doi.org\/10.1016\/j.jval.2024.04.018.","journal-title":"Value Health"},{"key":"855_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/17843286.2025.2519728","volume":"80","author":"A Meertens","year":"2025","unstructured":"Meertens A, Van Coile L, Shen A, Vossaert K, Waalboer-Spuij R, Van Wilder L, et al. Assessing health-related quality of life in patients with keratinocyte carcinoma: insights from a multicenter cross-sectional study. Acta Clin Belg. 2025;80:44\u201353. https:\/\/doi.org\/10.1080\/17843286.2025.2519728.","journal-title":"Acta Clin Belg"},{"key":"855_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.055","author":"M Alam","year":"2024","unstructured":"Alam M, Kim JYS, Swary JH, White LE, Ciurea A, Dave L, et al. Health utilities associated with nonmelanoma skin cancer. J Am Acad Dermatol [Internet]. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.055. [cited 2024 Feb 29].","journal-title":"J Am Acad Dermatol [Internet]"},{"key":"855_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/jvc2.227","volume":"2","author":"LG Gordon","year":"2023","unstructured":"Gordon LG, Lindsay D, Olsen CM, Whiteman DC. Health utilities and health-related quality of life of patients with keratinocyte skin cancers. JEADV Clin Pract. 2023;2:983\u201393. https:\/\/doi.org\/10.1002\/jvc2.227.","journal-title":"JEADV Clin Pract"},{"key":"855_CR22","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/cncr.23424","volume":"112","author":"JN Cormier","year":"2008","unstructured":"Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008;112:2249\u201357. https:\/\/doi.org\/10.1002\/cncr.23424.","journal-title":"Cancer"},{"key":"855_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2340\/00015555-2806","volume":"98","author":"R Waalboer-Spuij","year":"2018","unstructured":"Waalboer-Spuij R, Hollestein LM, Timman R, van de Poll-Franse LV, Nijsten TE. Development and Validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire. Acta Derm Venereol Swed. 2018;98:234\u20139. https:\/\/doi.org\/10.2340\/00015555-2806.","journal-title":"Acta Derm Venereol Swed"},{"key":"855_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/archfaci.8.5.314","volume":"8","author":"JS Rhee","year":"2006","unstructured":"Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg. 2006;8:314\u20138. https:\/\/doi.org\/10.1001\/archfaci.8.5.314.","journal-title":"Arch Facial Plast Surg"},{"key":"855_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/jdv.15487","volume":"33","author":"PV Chernyshov","year":"2019","unstructured":"Chernyshov PV, Lallas A, Tomas-Aragones L, Arenbergerova M, Samimi M, Manolache L, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. J Eur Acad Dermatol Venereol JEADV. 2019;33:816\u201327. https:\/\/doi.org\/10.1111\/jdv.15487.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"855_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2017;20:18\u201327. https:\/\/doi.org\/10.1016\/j.jval.2016.11.006.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"855_CR27","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jval.2011.04.003","volume":"14","author":"RL Askew","year":"2011","unstructured":"Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, et al. Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights. Value Health. 2011;14:900\u20136. https:\/\/doi.org\/10.1016\/j.jval.2011.04.003.","journal-title":"Value Health"},{"key":"855_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/bmj.318.7195.1413","volume":"318","author":"D Torgerson","year":"1999","unstructured":"Torgerson D, Raftery J. Measuring outcomes in economic evaluations. BMJ. 1999;318:1413. https:\/\/doi.org\/10.1136\/bmj.318.7195.1413.","journal-title":"BMJ"},{"key":"855_CR29","doi-asserted-by":"publisher","unstructured":"Bujkiewicz S, Ciani O, Heeg B, Lee D, Kusel JM, Thorlund K, et al. Methods for evaluation of surrogate endpoints for health technology assessment decision making: a good practices report of an ISPOR task force. Value Health [Internet]. 2026 [cited 2026 Ma [cited 2026 Mar 25]; https:\/\/doi.org\/10.1016\/j.jval.2026.01.020.","DOI":"10.1016\/j.jval.2026.01.020"},{"key":"855_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"P Thokala","year":"2016","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple Criteria Decision Analysis for Health Care Decision Making\u2014An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19:1\u201313. https:\/\/doi.org\/10.1016\/j.jval.2015.12.003.","journal-title":"Value Health"},{"key":"855_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14737167.2022.2019580","volume":"22","author":"AG Campolina","year":"2022","unstructured":"Campolina AG, Suzumura EA, Hong QN, de So\u00e1rez PC. Multicriteria decision analysis in health care decision in oncology: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2022;22:365\u201380. https:\/\/doi.org\/10.1080\/14737167.2022.2019580.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"855_CR32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jval.2019.06.014","volume":"22","author":"R Baltussen","year":"2019","unstructured":"Baltussen R, Marsh K, Thokala P, Diaby V, Castro H, Cleemput I, et al. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value Health. 2019;22:1283\u20138. https:\/\/doi.org\/10.1016\/j.jval.2019.06.014.","journal-title":"Value Health"},{"key":"855_CR33","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jval.2022.11.007","volume":"26","author":"P Gongora-Salazar","year":"2023","unstructured":"Gongora-Salazar P, Rocks S, Fahr P, Rivero-Arias O, Tsiachristas A. The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review. Value Health. 2023;26:780\u201390. https:\/\/doi.org\/10.1016\/j.jval.2022.11.007.","journal-title":"Value Health"},{"key":"855_CR34","doi-asserted-by":"publisher","unstructured":"van den Bogaart EHA, Kroese MEAL, Spreeuwenberg MD, Ruwaard D, Tsiachristas A. Economic evaluation of new models of care: does the decision change between cost-utility analysis and multi-criteria decision analysis? Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2021;24:795\u2013803.. https:\/\/doi.org\/10.1016\/j.jval.2021.01.014","DOI":"10.1016\/j.jval.2021.01.014"},{"key":"855_CR35","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/hex.12178","volume":"18","author":"G Adunlin","year":"2015","unstructured":"Adunlin G, Diaby V, Montero AJ, Xiao H. Multicriteria decision analysis in oncology. Health Expect Int J Public Particip Health Care Health Policy. 2015;18:1812\u201326. https:\/\/doi.org\/10.1111\/hex.12178.","journal-title":"Health Expect Int J Public Particip Health Care Health Policy"},{"key":"855_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2133.1997.tb14934.x","volume":"136","author":"AY Finlay","year":"1997","unstructured":"Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136:305\u201314.","journal-title":"Br J Dermatol"},{"key":"855_CR37","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.13237","volume":"171","author":"JR Chalmers","year":"2014","unstructured":"Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema\/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171:1318\u201325. https:\/\/doi.org\/10.1111\/bjd.13237.","journal-title":"Br J Dermatol"},{"key":"855_CR38","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s11136-023-03443-9","volume":"32","author":"M Franklin","year":"2023","unstructured":"Franklin M, Hern\u00e1ndez Alava M. Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models. Qual Life Res. 2023;32:2763\u201378. https:\/\/doi.org\/10.1007\/s11136-023-03443-9.","journal-title":"Qual Life Res"},{"key":"855_CR39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1192\/bjp.bp.110.082453","volume":"197","author":"J Brazier","year":"2010","unstructured":"Brazier J. Is the EQ\u20135D fit for purpose in mental health? Br J Psychiatry. 2010;197:348\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.110.082453.","journal-title":"Br J Psychiatry"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00855-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:42:10Z","timestamp":1792665730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00855-5"}},"subtitle":["A decision matrix to guide transparent outcome selection in skin cancer health economic evaluations, supporting more informed decision-making"],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00855-5","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}